Angiodynamics, Inc. (DE:UG2)
NASDAQ:UG2
Earnings Data
Report Date
Jul 21, 2026Before Open (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.03Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum driven by Med Tech platforms (Auryon, AlphaVac/AngioVac, NanoKnife), multiple product- and regulatory-level achievements, and upward revisions to revenue and adjusted EBITDA guidance — all positive indicators. Notable headwinds include a 110-bp gross margin decline tied to tariffs and manufacturing transition, an expected $4M–$6M tariff hit for FY2026, a planned $3M–$5M inventory build that may slightly depress FY cash flow, and continued adjusted net losses. On balance, the operational wins, raised guidance, and sustained product adoption outweigh the identified near-term margin and cash pressures.Company Guidance
Quarterly Revenue Growth and Raised Full-Year Guidance
Total revenue increased 8.9% YoY to $78.4M in Q3. Management raised FY2026 net sales guidance to $313.5M-$315.5M (up from $312M-$314M), implying 7.1%–7.8% growth vs FY2025. Adjusted EBITDA guidance was raised to $10M-$12M (from $8M-$10M).
Med Tech Segment Momentum
Med Tech revenue was $37.3M, up 19.0% YoY and now represents 48% of company revenue versus 44% a year ago (YTD Med Tech +19.1%), reflecting favorable portfolio mix shift into higher-growth, higher-margin markets.
Auryon: Long-Running Durable Growth
Auryon revenue was $16.3M, up 17.9% YoY and marking the 19th consecutive quarter of double-digit YoY growth. Management attributes growth to product extensions and increased hospital adoption (higher price/volume mix).
Mechanical Thrombectomy — Rapid Adoption (AlphaVac & AngioVac)
Combined Mechanical Thrombectomy revenue was $11.5M, up 17.9% YoY. AlphaVac grew to $4.4M (+47.4% YoY and >24% sequential increase vs Q2), while AngioVac was $7.2M (+5% YoY). Company enrolled first patients in the APEX-Return pivotal trial with an expected approval process targeted in Q1 2027 — a potential adoption catalyst.
NanoKnife: Strong Disposable and Capital Growth, Reimbursement & Regulatory Progress
NanoKnife revenue totaled $7.6M, up 21% YoY; probes increased ~20% and capital sales rose 24.9%. CPT 1 Code became effective Jan 1 and company announced expanded European indications for liver, pancreas, kidney and prostate soft tissue ablation.
Profitability Improvements and Financial Position
Adjusted EBITDA improved to $1.8M in Q3 (from $1.3M prior year). Adjusted net loss narrowed slightly to $3.0M ($0.07/sh) from $3.1M ($0.08/sh). Company maintains zero debt and a strong balance sheet; expects substantial cash generation in Q4 consistent with historical seasonality.
Commercial Execution and Training Momentum
Sales momentum driven by hospital site-of-care wins and uptake of training/clinical education programs. Management highlighted new accounts, increasing utilization in existing accounts, and physician demand as drivers of sustained growth.
DE:UG2 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:UG2 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 02, 2026 | €10.10 | €8.95 | -11.39% |
Jan 06, 2026 | €11.20 | €9.75 | -12.95% |
Oct 02, 2025 | €9.35 | €10.00 | +6.95% |
Jul 15, 2025 | €8.05 | €7.35 | -8.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Angiodynamics, Inc. (DE:UG2) report earnings?
Angiodynamics, Inc. (DE:UG2) is schdueled to report earning on Jul 21, 2026, Before Open (Confirmed).
What is Angiodynamics, Inc. (DE:UG2) earnings time?
Angiodynamics, Inc. (DE:UG2) earnings time is at Jul 21, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Angiodynamics, Inc. stock?
The P/E ratio of AngioDynamics is N/A.
What is DE:UG2 EPS forecast?
DE:UG2 EPS forecast for the fiscal quarter 2026 (Q4) is -0.08.
